Johnson & Johnson Unveils Multiple Global Leading Healthcare Innovations at CIIE

China Finance and Economics News, November 5th: The 7th China International Import Expo officially opened today.

On the first day of the CIIE, Johnson & Johnson, focusing on core health issues such as rewriting the history of cancer, conquering cardiovascular and cerebrovascular diseases, building a healthy "aging" society, and pushing the boundaries of medical technology, released several globally leading healthcare innovation products and solutions. Additionally, Johnson & Johnson held the China premiere of its new global brand promotional video, "Innovation in Action, Care at Heart (Health&Care)."

Based on the significant clinical demand for EGFR-mutated non-small cell lung cancer in China, Johnson & Johnson Innovative Pharmaceuticals showcased Rybrevant, an innovative drug for treating EGFR-mutated non-small cell lung cancer. Rybrevant is the world's first approved EGFR/MET bispecific antibody for the treatment of non-small cell lung cancer.

In addition to cancer, cardiovascular and cerebrovascular diseases have become another major threat to the health of Chinese people. In this field, Johnson & Johnson has brought four exhibits that are either debuting in China or globally for the first time: the groundbreaking product in heart failure treatment, Impella CP with SmartAssist, an interventional left ventricular assist pump; and the innovative paddle-designed, single-use magnetic positioning mapping catheter OPTRELL.^™; STSF multi-electrode cavity catheter with intelligent precise pressure indication and multi-hole perfusion technology; PRONOVA, a new generation of single-strand non-absorbable suture with strong and continuous suturing, mainly used in cardiovascular minimally invasive surgery.

In response to the global health and even social issue of population aging, Johnson & Johnson Vision introduces two products making their debut in China: the innovative intraocular lens TECNIS Odyssey, specifically designed to provide full-range vision.^™Acuvue, Johnson & Johnson^®Oushushi^®Max Multifocal Contact Lenses.

For multiple myeloma, the second most common malignant hematologic tumor predominantly affecting the elderly population, its incurable and highly recurrent nature poses significant survival challenges for middle-aged and elderly individuals. Johnson & Johnson Innovative Pharmaceuticals has introduced two innovative drugs for multiple myeloma, including Talvey, the world's first T-cell redirecting bispecific antibody that simultaneously binds to the CD3 receptor complex on T cells and GPRC5D on plasma cells; and Tecvayli, the first and currently only ready-to-use bispecific antibody launched in China, which offers more patients with relapsed or refractory multiple myeloma the opportunity to achieve deeper remission and longer survival, moving towards functional cure.

Cherry Huang, President of Johnson & Johnson Innovative Medicine China, stated: "The CIIE provides a broad platform for exchange and cooperation for multinational healthcare companies, including Johnson & Johnson, and also brings us opportunities to jointly build a healthy future for China. Over the seven 'CIIE appointments,' we are delighted to see that several innovative drugs from Johnson & Johnson Innovative Medicine have been accelerated to market through the CIIE platform, bringing health benefits to Chinese patients as soon as possible. In the future, we look forward to continuing to collaborate with all parties in the industry to meet the health needs of more people in China and contribute to China's healthcare cause."

Johnson & Johnson Medical Technologies innovates at the intersection of biology and technology, continuously pushing the boundaries of science to deliver smarter, minimally invasive, and more personalized products and solutions. Johnson & Johnson Medical Technologies China launched the latest generation of pre-installed chip staplers, the Echelon 3000 Stapler, and the first high-frequency surgical device in China, the Megadyne Maiyun High-Frequency Surgical Device. Through innovative algorithm analysis, these devices reduce tissue damage to patients and ensure patient safety. Globally, Johnson & Johnson Medical Technologies introduced the new generation of antibacterial Vicryl.^®The Trocar Needle, a brand-new product developed by the Chinese team based on insights into clinical customer needs in China, is manufactured in China and has been launched in the Chinese market first.

Zhou Mintao, President of Johnson & Johnson Medical Technology China, stated that Johnson & Johnson Medical Technology not only comprehensively showcases globally leading medical technology products and solutions at the CIIE but also accelerates the introduction of numerous innovative exhibits into the Chinese market. Additionally, it promotes "Made in China" innovative products, which are locally produced in China, to the global market.